CN112876565B - Colorectal cancer detection kit - Google Patents
Colorectal cancer detection kit Download PDFInfo
- Publication number
- CN112876565B CN112876565B CN202110249959.9A CN202110249959A CN112876565B CN 112876565 B CN112876565 B CN 112876565B CN 202110249959 A CN202110249959 A CN 202110249959A CN 112876565 B CN112876565 B CN 112876565B
- Authority
- CN
- China
- Prior art keywords
- cea
- seq
- variable region
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
The invention relates to the field of tumor immunodetection, in particular to a colorectal cancer detection kit, and also discloses application of an antibody in preparation of a tumor treatment and/or diagnosis reagent. The application of the kit provides an effective tool for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of colon cancer and rectal cancer patients.
Description
Technical Field
The invention relates to the technical field of immunodetection, and particularly relates to a colorectal cancer detection kit.
Background
Colorectal malignancies are currently one of the most common tumors in the world. In developed countries in europe and america, the incidence rate is second to malignant tumors and third to the world, and men are second to lung cancer and gastric cancer, while women are second to breast cancer and cervical cancer. Colorectal cancer is most common in north america, western european australia, and new zealand, among other countries. In China, the incidence of colorectal cancer is fifth in men and fifth in women. Compared with developed countries, the onset age of colorectal cancer in China is obviously advanced, and the median onset age is about 45 years old. Moreover, the incidence of colorectal cancer continues to be strongly rising with the recent improvement of living standard.
Carcinoembryonic antigen (CEA) is a soluble glycoprotein with a complex structure, a molecular weight of about 200kDa, and is mainly present in the gastrointestinal tract, pancreas and liver of a fetus during the embryonic period, and has a very low postnatal tissue content. CEA levels are abnormally elevated in the serum of patients with gastrointestinal malignancies, breast cancer, carcinomas and other malignancies. The expression of the CEA in colorectal cancer is the highest (60-90%), so that the CEA content can be used as an effective index for prognosis judgment, curative effect observation, tumor focus metastasis or recurrence monitoring and the like of patients with colon cancer and rectal cancer, can be used as an independent prognostic factor, and receives more and more attention.
At present, various anti-CEA antibody patents are published at home and abroad, such as W02004032962, W02011034660, W02012l17002, CN103173417 and the like. Monoclonal antibodies with higher affinity and more favorable properties are still needed. Has important significance for prognosis judgment, curative effect observation and diagnosis and scientific research of monitoring the metastasis or relapse of tumor lesions of patients with colon cancer and rectal cancer.
Disclosure of Invention
The invention aims to provide a CEA antibody which has high affinity and can be used for detecting carcinoembryonic antigen aiming at the defects in the prior art.
The invention provides the following technical scheme:
an anti-CEA monoclonal antibody, consisting of a heavy chain and a light chain, which comprise a variable region and a constant region, respectively, wherein the heavy chain variable region is selected from SEQ ID NO. 7 and the light chain variable region is selected from SEQ ID NO. 8.
The anti-CEA monoclonal antibody heavy and light chain variable region of the invention has 6 complementarity determining regions. The 3 CDR sequences of the heavy chain variable region of the anti-CEA monoclonal antibody are respectively SEQ ID NO 1, SEQ ID NO 2 and SEQ ID NO 3; the variable region of light chain has 3 CDR sequences of SEQ ID NO 4, SEQ ID NO 5 and SEQ ID NO 6.
The heavy and light chains of the anti-CEA monoclonal antibody of the invention further comprise constant regions, and the antibody light chain constant region further comprises murine kappa and lambda chain sequences. The antibody heavy chain constant region further comprises a murine IgG1, IgG2a, IgG2b, or IgG3, or IgA or IgM sequence.
The invention also aims to provide a CEA quantitative detection kit, a preparation method and application thereof. The kit comprises the CEA-recognizing antibody, and is used for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of colon cancer and rectal cancer patients.
The CEA quantitative detection kit comprises an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme-labeled antibody.
The anti-CEA enzyme-labeled antibody is a CEA polyclonal antibody marked by horseradish peroxidase. The preparation method of the polyclonal antibody and the method of the enzyme-labeled antibody are all routine operations in the field.
Further, the quantitative detection kit also comprises a CEA standard substance, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution.
The anti-CEA monoclonal antibody, a CEA standard substance, a horseradish peroxidase labeled anti-CEA polyclonal antibody, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution are respectively put into each reagent bottle, and each reagent bottle is fixed by a sponge bracket and is arranged in a kit body together with an ELISA plate and a sealing plate membrane which are coated by the CEA antibody.
Advantageous effects
The invention has the following beneficial effects: provides a new CEA antibody with high affinity, which can be used for carcinoembryonic antigen detection; the CEA detection kit established by the antibody of the invention has the advantages of simple and easy operation, quick and sensitive detection, simple and popular enzyme labeling instrument and low price, and provides an effective tool for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of patients with colon cancer and rectal cancer.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention.
FIG. 1 subtype identification of mouse monoclonal antibodies
FIG. 2 anti-CEA antibody specificity: does not cross react with MA, NCA and the like
FIG. 3 is a standard curve for detecting carcinoembryonic antigen CEA by the carcinoembryonic antigen detection kit of the present invention
Detailed Description
The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
Example 1 anti-CEA antibody preparation and purification
Culturing CHO cells stably expressing CEA in DMEM medium, and culturing 107CHO-CEA+Cells were injected intraperitoneally with Freund's complete adjuvant in female Balb/c mice for primary immunization followed by 10 more times every 2 weeks7CHO-CEA+Cells were injected intraperitoneally into the female Balb/c mice and immunization was continued. Finally, the last immunization is carried out 3 days before the fusion with the myeloma cells, and the last immunization is 107CHO-CEA+Cells are immunized intravenously. Spleen cells of immunized Balb/c mice were fused with a myeloma Sp2/0 cell line, and the fused cells were diluted to an appropriate concentration in Iscove's medium (0.1mM hypoxanthine, 0.4. mu.M aminopterin and 16. mu.M thymidine) containing 10% serum, and then cultured in a 96-well plate. After 10 days, cell supernatants were taken and primary cultures showing positive reaction with recombinant CEA protein in the supernatants were examined by high throughput ELISA. Then hybridizing the wellsAnd (3) diluting the tumor cells for subcloning, and screening by an ELISA method to finally obtain a positive hybridoma cell strain. After expansion culture, the hybridoma cells were cryopreserved.
BALB/c mice were injected intraperitoneally with 0.5 ml/mouse, 1 week before hybridoma inoculation. After 1 week, each mouse was inoculated intraperitoneally at about 1X106(ii) individual hybridoma cells; and after 7-10 days, collecting ascites. Centrifuging ascites at 10000 Xg for 30min, removing precipitate, salting out with 50% ammonium sulfate, coarse extracting, dissolving with PBS, and dialyzing with flowing water for 5 hr; dialyzing and equilibrating with 0.1mol/L phosphate buffer (pH8.0) overnight; and (3) loading, eluting the hybrid protein by using 0.1mol/L phosphate buffer solution (pH8.0), eluting by using citrate eluents with different pH values, collecting elution peaks in sections, concentrating, analyzing and purifying the purity of the monoclonal antibody by 10 percent SDS-PAGE, and determining the titer by an indirect ELISA method. Through indirect ELISA detection, the titer of 8 mAbs can reach 1: 108。
Example 2 anti-CEA antibody subtype identification
The subtype of the anti-CEA monoclonal antibody Cab-207 obtained in example 1 was identified by ELISA (kit purchased from Proteintech). The microplate provided in the kit was already pre-coated with specific antibodies against mouse IgG1, IgG2a, IgG2b, IgG3, IgA, IgM, kappa light chain, lambda light chain, and the anti-CEA antibody sample Cab-207 purified in example 1 was added to the sample well at 50. mu.l per well without incubation. Adding 1X goat anti-mouse IgA + IgM + IgG-HRP into sample wells, mixing the sample wells with 50 μ l each, and incubating for 1 h. And (4) deducting liquid in the holes, adding 1XPBST to wash the holes for 3 times, and absorbing the excessive moisture by absorbent paper. Adding color development solution, and developing 100 μ l per well in dark at room temperature for 15 min. The color reaction was stopped by adding 100. mu.l of stop solution. The OD value at 450nm was measured by a microplate reader, and the results are shown in FIG. 1, in which all the heavy chain subtypes and all the light chain subtypes of the obtained anti-CEA monoclonal antibody Cab-207 are IgG 1.
EXAMPLE 3 monoclonal antibody sequencing
After the hybridoma cell strain corresponding to Cab-207 is recovered, the hybridoma cell strain is cultured until the total number is 107The cells were centrifuged at 1000rpm for 5min to collect the cells, and RNA was extracted. TRNzol-A + was added to the cell pellet for lysis and allowed to stand at room temperature for 15 min. TRNzo per mlMu.l of chloroform was added to the solution of l-A +, and the mixture was vortexed for 15 seconds and allowed to stand for 3 minutes. After centrifugation at 13000rpm for 10 minutes at 4 ℃, Trizol-A + cell solution is divided into three layers: transferring the water phase dissolved with the RNA into a centrifuge tube, adding isopropanol with the same volume into the water phase, uniformly mixing, and standing at room temperature for 25 minutes. 13000rpm, 4 ℃ centrifugal 10 minutes, discarded waste liquid to get the bottom of the RNA precipitation. After washing the RNA pellet twice with 75% ethanol, the RNA was dissolved in PEDC water and stored at-80 ℃. Synthesizing first chain cDNA by reverse transcription kit SMARTERRACE, and amplifying antibody variable region DNA sequence corresponding to hybridoma cell by using the first chain cDNA as subsequent template. Designing specific nested PCR primer, the primer sequence used in the amplification reaction is complementary with the first frame region and the constant region of the antibody variable region, and amplifying the target gene by adopting a conventional PCR method. Sequencing the amplified product to obtain the heavy chain variable region sequence SEQ ID NO:7 and light chain variable region sequences SEQ ID NO: 8; the 3 CDR sequences of the heavy chain variable region of the antibody are respectively SEQ ID NO 1, SEQ ID NO 2 and SEQ ID NO 3; the variable region of light chain has 3 CDR sequences of SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.
Example 4 identification of antibody specificity
The monoclonal antibody purified in example 1 was cross-reacted with the CEA, MA, NCA coated ELISA plate by indirect ELISA, and the specificity was analyzed. The specific experimental process is to coat CEA, MA and NCA (all from Fitzgerald) respectively at a concentration of 0.1mg/ml, add the antibody obtained in example 1 to three different coating antigens respectively, and detect the degree of cross reaction by indirect ELISA. As shown in FIG. 2, the anti-CEA monoclonal antibody Cab-207 reacted only with CEA and did not cross-react with MA and NCA.
Example 5 affinity assay for anti-CEA antibodies
Coating an antibody capture Antibody (AHC) on the surface of a CM5 chip by an amino coupling mode, preparing chip activation buffer solution N-ethyl-N' - (3-dimethylaminopropyl) -carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), AHC and ethanolamine for blocking according to the specifications of an amino coupling kit and an anti-capture kit, and selecting the coating in a Biacore3000 systemProcedure AHC amino groups were coupled to the CM5 chip surface. The anti-CEA antibody Cab-207 obtained in example 1 was captured on the chip surface. The antibody was diluted to 1. mu.g/mL with HBS-EP + buffer, set to a flow rate of 5. mu.L/min, and coated to a response value of 300 RU. CEA antigen was set up in 7 different concentration gradients and serially diluted in HBS-EP buffer in 2-fold gradients from 200nM to 3.125 nM. The flow rate of CEA antigen was set at 30. mu.L/min and the binding time was set at 3 min. The flow rate of HBS-EP + buffer is set to be 30 mu L/min, and the dissociation time is set to be 10 min. Use of 3M MgCl2As a regeneration buffer, the chip was regenerated according to the regeneration procedure. In addition, affinity assay was performed according to the same procedure with reference to antibody sanofi (antibody light and heavy chain variable region sequences are shown in SEQ ID NO:9, 10, respectively). Calculation of binding Rate (K) by Simultaneous fitting of binding and dissociation sensorgramsa) And dissociation Rate (K)d). Equilibrium dissociation constant (K)d) Using dissociation rate (K)d) Rate of binding (K)a) And (4) calculating. The results are shown in table one: compared with the control antibody, the antibody of the invention has higher affinity, and the affinity KDThe value reaches 1.55x10-9M。
| Antibodies | Ka(1/Ms) | Kd(1/s) | KD(M) |
| Cab-207 | 6.91x104 | 1.07x10-4 | 1.55x10-9 |
| sanofi | 4.11x104 | 1.91x10-3 | 4.65x10-8 |
Example 6 preparation of CEA quantitative immunoassay kit (first) preparation of ELISA plate
The anti-CEA monoclonal antibody Cab-207 obtained in example 1 was diluted to 0.5. mu.g/ml with 0.01M phosphate buffer solution and the pH was 7.0 to 7.4 to obtain a coating solution. Adding 3% of skimmed milk powder into 0.01M phosphate buffer solution with the pH value of 7.0-7.4 to prepare confining liquid. Adding the prepared coating solution into the holes of an enzyme-labeled plate, and adding 100 mu L of the coating solution into each hole; the enzyme label plate is placed in an environment of 4 ℃ for coating overnight; adding the prepared confining liquid into the pores of an enzyme-labeled plate, adding 100 mu L of confining liquid into each pore, and placing the pores in a 37 ℃ incubator for 30 minutes; the enzyme label plate is taken out from the incubator, the confining liquid is discarded, and the temperature is kept constant at 37 ℃ for 30 minutes.
(II) preparing enzyme-labeled antibody solution
Immunizing a rabbit with the CEA antigen to obtain an anti-CEA polyclonal antibody, and labeling the anti-CEA polyclonal antibody with horseradish peroxidase to obtain an enzyme-labeled antibody. Firstly, weighing a proper amount of HRP enzyme, dissolving the HRP enzyme in triple distilled water, adding a newly-prepared sodium periodate solution, uniformly mixing, and then placing at 4 ℃ for 30 min; adding ethylene glycol solution, and standing at room temperature for 30 min; adding appropriate amount of purified antibody, mixing, adjusting pH to 9.0, standing at 4 deg.C overnight; adding sodium borohydride, mixing, and standing at 4 deg.C for 2 hr; adding the enzyme-labeled antibody mixed solution into an isovolumetric saturated ammonium sulfate solution, and standing at 4 ℃ for 30 min; after centrifugation, the mixture was dialyzed overnight against a phosphate buffer solution of pH 7.4.
(III) preparing CEA standard substance
CEA antigen: commercially available from Fitzgerald corporation.
(IV) preparation of concentrated Wash solution (20X 0.01M PBS)
Mixing 96 parts of sodium chloride, 2.4 parts of potassium chloride, 42.96 parts of disodium hydrogen phosphate dodecahydrate, 2.88 parts of potassium dihydrogen phosphate, 200.05 parts of tween-and 1000 parts of ultrapure water uniformly to obtain the finished product.
(V) substrate solution (TMB)
TMB Tetramethylbenzidine (3,3 ', 5, 5' -Tetramethylbenzidine), available from Tiangen, Beijing.
(VI) preparing stop solution (2mol/L sulfuric acid solution)
Diluting concentrated sulfuric acid and ultrapure water by 1: 8 to prepare stop solution.
Example 7 determination of the detection Range of the CEA quantitative immunoassay kit
CEA antigen was diluted with artificial serum in a gradient of 1000, 400, 200, 100, 50, 20, 5, 1, 0.2 ng/ml. Detection was performed using the kit of example 6. And (3) drawing a standard curve by taking the CEA antigen concentration as an abscissa and the corresponding A450 as an ordinate to obtain a fitting regression equation, and selecting the CEA antigen concentration range with the best linear relation as the optimal detection range of the detection reagent. The final data are shown in fig. 3, and the detection results show that when the CEA concentration is 0.2-400ng/ml, the linear relationship with the corresponding a450 value is good, R2 is 0.997, and the regression equation is: y is 0.0041x +0.216, and the lowest detection line is 0.09 ng/ml.
Example 8 kit stability assay
In order to test the stability and accuracy of the carcinoembryonic antigen CEA quantitative detection kit in example 6, the kit in example 6 was subjected to performance every 2 months, an ELISA plate was coated with an anti-CEA antibody Cab-207, stored at 4 ℃ for 3 months, subjected to standard protein detection again, and a standard curve was drawn. CEA antigen was diluted with artificial serum in a gradient manner to concentrations of 1000, 400, 200, 100, 50, 20, 5, 1, 0.2 ng/ml. Detection was performed using the kit of example 6. And (3) drawing a standard curve by taking the CEA antigen concentration as an abscissa and the corresponding A450 as an ordinate to obtain a fitting regression equation. The test results are shown in table 2, and the results show that the linear correlation between the carcinoembryonic antigen CEA detection kit of the embodiment 6 and the luminescence value is kept above 0.99 for 10 consecutive months, and the lowest detection limit is less than 0.15, which shows that the kit of the invention has higher stability and repeatability.
TABLE 2
Sequence listing
<110> Beijing Vast Mei Biotechnology Ltd
<120> colorectal cancer detection kit
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Thr Ala Gly Met Asn
1 5
<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Asp Ile Asn Tyr Gly Glu Asp Val Pro Thr Ala Ser Glu Asp Phe Lys
1 5 10 15
Gly
<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Ser Gly Asn Tyr Val Gly Arg Trp Asp Phe Asp Tyr
1 5 10
<210> 4
<211> 15
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Arg Ala Gly Asn Ser Val Glu Ile Cys Gly Asn Thr Asn Leu His
1 5 10 15
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Gly Thr Asn Ser Ala Glu Thr
1 5
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gln Gln Ala Ser Trp Ile Phe Tyr Thr
1 5
<210> 7
<211> 121
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Ala
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
Gly Asp Ile Asn Tyr Gly Glu Asp Val Pro Thr Ala Ser Glu Asp Phe
50 55 60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Asn Tyr Val Gly Arg Trp Asp Phe Asp Tyr Trp Gly
100 105 110
Thr Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> 8
<211> 111
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Met Ser Leu Gly
1 5 10 15
Lys Arg Ala Thr Ile Ser Cys Arg Ala Gly Asn Ser Val Glu Ile Cys
20 25 30
Gly Asn Thr Asn Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Gly Thr Asn Ser Ala Glu Thr Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Asp
65 70 75 80
Pro Val Glu Gly Asp Asp Val Ala Leu Tyr Tyr Cys Gln Gln Ala Ser
85 90 95
Trp Ile Phe Tyr Thr Phe Gly Gly Gly Thr Lys Met Glu Ile Lys
100 105 110
<210> 9
<211> 120
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Ser Tyr
20 25 30
Asp Met Ser Trp Val Arg Gln Thr Pro Glu Arg Gly Leu Glu Trp Val
35 40 45
Ala Tyr Ile Ser Ser Gly Gly Gly Ile Thr Tyr Ala Pro Ser Thr Val
50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala His Tyr Phe Gly Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 10
<211> 107
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Phe Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Val
35 40 45
Tyr Asn Thr Arg Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Phe
85 90 95
Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105
Claims (8)
1. A CEA antigen quantitative detection kit is characterized by comprising an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme label antibody, wherein the anti-CEA monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR1 shown in SEQ ID NO. 1, a CDR2 shown in SEQ ID NO. 2 and a CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a CDR1 shown in SEQ ID NO. 4, a CDR2 shown in SEQ ID NO. 5 and a CDR3 shown in SEQ ID NO. 6.
2. A CEA antigen quantitative detection kit is characterized by comprising an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme labeled antibody, wherein the anti-CEA monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises an amino acid sequence shown in SEQ ID NO. 7, and the light chain variable region comprises an amino acid sequence shown in SEQ ID NO. 8.
3. The kit for quantitatively detecting the CEA antigen according to claim 1 or 2, characterized in that the anti-CEA enzyme-labeled antibody is a horseradish peroxidase-labeled anti-CEA polyclonal antibody.
4. The kit for quantitatively detecting a CEA antigen according to any one of claims 1 to 3, wherein the kit for quantitatively detecting a CEA antigen further comprises a CEA standard, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution.
5. An anti-CEA monoclonal antibody comprising a heavy chain variable region comprising CDR1 shown in SEQ ID NO. 1, CDR2 shown in SEQ ID NO. 2 and CDR3 shown in SEQ ID NO. 3, and a light chain variable region comprising CDR1 shown in SEQ ID NO. 4, CDR2 shown in SEQ ID NO. 5 and CDR3 shown in SEQ ID NO. 6.
6. The anti-CEA monoclonal antibody is characterized by comprising a heavy chain variable region comprising an amino acid sequence shown in SEQ ID NO. 7 and a light chain variable region comprising an amino acid sequence shown in SEQ ID NO. 8.
7. Use of the anti-CEA monoclonal antibody according to claim 5 or 6 for the preparation of a reagent for the detection of CEA antigens in cancer patients.
8. Use according to claim 7, characterized in that: the cancer is colon cancer and rectal cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110249959.9A CN112876565B (en) | 2021-03-08 | 2021-03-08 | Colorectal cancer detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110249959.9A CN112876565B (en) | 2021-03-08 | 2021-03-08 | Colorectal cancer detection kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112876565A CN112876565A (en) | 2021-06-01 |
| CN112876565B true CN112876565B (en) | 2021-09-17 |
Family
ID=76055675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110249959.9A Active CN112876565B (en) | 2021-03-08 | 2021-03-08 | Colorectal cancer detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112876565B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101065393A (en) * | 2004-09-30 | 2007-10-31 | 优基谱 | Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods, and kits thereof |
| CN101607985B (en) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | Monoclonal antibody for anti-human CEA, a composition containing same and application thereof |
| CN112342295A (en) * | 2019-08-06 | 2021-02-09 | 中山大学孙逸仙纪念医院 | Tumor marker for detecting human colorectal cancer and application thereof |
| CN111187351B (en) * | 2020-04-14 | 2020-08-04 | 浙江恒驭生物科技有限公司 | Liver cancer detection kit |
-
2021
- 2021-03-08 CN CN202110249959.9A patent/CN112876565B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112876565A (en) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9823251B2 (en) | Anti-Uroplakin II antibodies systems and methods | |
| CN112094348B (en) | Anti-human Tim3 antibody or functional fragment thereof and application thereof | |
| CN116375856A (en) | anti-Tau protein monoclonal antibody 1A5-47H7, product based on same and application | |
| CN111363037B (en) | Disease detection kit containing antibody specifically binding AFP protein | |
| CN112898430B (en) | Binding protein of CA242, application thereof, detection method and kit | |
| CN110105449B (en) | Antibody specifically binding VEGF and application | |
| CN112876565B (en) | Colorectal cancer detection kit | |
| CN112251414A (en) | Hybridoma cell strain, preparation method and application thereof | |
| CN112557662B (en) | Colorectal cancer detection kit | |
| CN112710835B (en) | Reproductive system disease detect reagent box | |
| CN115925866A (en) | Monoclonal antibody for breast cancer detection and kit thereof | |
| JPWO2009044561A1 (en) | Anti-proNT / NMN monoclonal antibody | |
| CN112646037B (en) | anti-CD 105 specific monoclonal antibody and application thereof | |
| CN110031616B (en) | Detection kit for auxiliary diagnosis of diseases | |
| CN110133278B (en) | In-vitro kit for detecting human VEGF protein expression level | |
| CN112684175B (en) | Kit for detecting ovarian cancer | |
| CN112500488B (en) | Cancer detection kit | |
| CN110579610A (en) | Kit for detecting V-domain immunosuppressive factor activated by T cells | |
| CN112694533B (en) | Reproductive system disease detection kit | |
| CN111793136A (en) | NMP22 antibody pair and application thereof | |
| CN113186284B (en) | Nucleic acid-antibody dual cancer detection kit | |
| CN113249445B (en) | Nucleic acid-antibody dual cancer detection kit | |
| WO2014146487A1 (en) | Anti-cell surface ectopic expression monoclonal antibody, preparation method and use thereof | |
| CN109776679B (en) | Antibody of serine protease inhibitor SPINK1, and preparation method and application thereof | |
| CN108948205B (en) | anti-IDH 1R132H monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210827 Address after: 523000 room 1001 and 1101, building 1, No. 14, Gongye West Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant after: Guangdong Mingzhi medical laboratory Co.,Ltd. Address before: 201-134, 2 / F, building 23, courtyard 8, Dongbei Wangxi Road, Haidian District, Beijing Applicant before: Beijing Hanmei Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Colorectal cancer detection kit Effective date of registration: 20221121 Granted publication date: 20210917 Pledgee: Dongguan branch of Bank of Dongguan Co.,Ltd. Pledgor: Guangdong Mingzhi medical laboratory Co.,Ltd. Registration number: Y2022440000310 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |